Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rebound effect08.06.02.0090.000313%Not Available
Rectal cancer16.13.01.003; 07.21.05.002--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.003039%
Rectal polyp07.20.01.005; 16.05.02.0030.000313%Not Available
Renal colic20.02.03.010--
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.0050.003446%Not Available
Respiratory disorder22.02.07.0020.000470%Not Available
Respiratory distress22.02.01.0120.001253%Not Available
Respiratory failure14.01.04.003; 22.02.06.0020.002506%
Retching07.01.07.002--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.0010.000313%Not Available
Retinal vasculitis10.02.02.021; 06.04.06.0110.000313%Not Available
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.001253%Not Available
Rhinitis allergic10.01.04.003; 22.04.04.0030.000313%
Rhinorrhoea22.12.03.0210.000627%
Rosacea23.02.08.0010.001065%Not Available
Sarcoidosis10.02.06.0010.000470%Not Available
Sarcoma15.09.03.002; 16.33.01.002--Not Available
Scab23.03.03.004--Not Available
Sciatica17.10.03.001; 15.10.01.001--Not Available
Scoliosis15.10.04.001--
Sensory disturbance17.02.07.0060.000470%Not Available
Sensory loss17.02.07.0070.000313%Not Available
Serum sickness10.01.03.004; 12.02.08.0040.000470%
Shock24.06.02.0020.001567%Not Available
Sinus congestion22.04.06.001--Not Available
Skin cancer23.08.02.002; 16.03.02.0020.000940%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene